These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25518257)

  • 1. Grey matter atrophy in patients suffering from multiple sclerosis.
    Kincses ZT; Tóth E; Bankó N; Veréb D; Szabó N; Csete G; Faragó P; Király A; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Sep; 67(9-10):293-300. PubMed ID: 25518257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of the washout time between natalizumab and fingolimod.
    de Seze J; Ongagna JC; Collongues N; Zaenker C; Courtois S; Fleury M; Benoilid A; Chanson JB; Blanc F;
    Mult Scler; 2013 Aug; 19(9):1248. PubMed ID: 23722322
    [No Abstract]   [Full Text] [Related]  

  • 3. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
    Sormani MP; Bonzano L; Roccatagliata L; De Stefano N
    Mult Scler; 2011 May; 17(5):630-3. PubMed ID: 21177320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging disease-modifying oral therapies for multiple sclerosis.
    Losy J; Kalinowska-Łyszczarz A
    J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seeing injectable ms therapies differently: they are more similar than different.
    Johnson KP; Fox RJ; Arnold DL
    Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129
    [No Abstract]   [Full Text] [Related]  

  • 7. Time to talk about timing--when to start, stop and change anti-migratory drugs in MS.
    Stüve O; Hemmer B
    Mult Scler; 2012 Nov; 18(11):1514-6. PubMed ID: 23100520
    [No Abstract]   [Full Text] [Related]  

  • 8. [Multiple sclerosis: current therapies and future perspectives].
    Matsushita T
    Nihon Rinsho; 2011 Nov; 69(11):2077-86. PubMed ID: 22111333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the origins of grey matter damage in multiple sclerosis.
    Calabrese M; Magliozzi R; Ciccarelli O; Geurts JJ; Reynolds R; Martin R
    Nat Rev Neurosci; 2015 Mar; 16(3):147-58. PubMed ID: 25697158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.
    Calabrese M; Gajofatto A; Benedetti MD
    Expert Rev Neurother; 2014 Dec; 14(12):1417-28. PubMed ID: 25391525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [2012: Update on diagnosis and treatment of multiple sclerosis].
    Havla J; Kümpfel T; Hohlfeld R
    Dtsch Med Wochenschr; 2012 Apr; 137(17):894-9. PubMed ID: 22492476
    [No Abstract]   [Full Text] [Related]  

  • 12. Cortical lesion load associates with progression of disability in multiple sclerosis.
    Calabrese M; Poretto V; Favaretto A; Alessio S; Bernardi V; Romualdi C; Rinaldi F; Perini P; Gallo P
    Brain; 2012 Oct; 135(Pt 10):2952-61. PubMed ID: 23065788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.
    Rudick RA
    J Neuroimaging; 2004 Jul; 14(3 Suppl):54S-64S. PubMed ID: 15228760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
    Agashivala N; Kim E
    Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current treatment of multiple sclerosis].
    Csépány T
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J
    Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
    Jander S; Turowski B; Kieseier BC; Hartung HP
    Mult Scler; 2012 Nov; 18(11):1650-2. PubMed ID: 23100527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.
    Fox RJ
    Mult Scler; 2013 Jan; 19(1):24-5. PubMed ID: 23303880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.